Overcoming resistance to antiangiogenic therapies. - Wikidata - awgldk - TriplyDB

Overcoming resistance to antiangiogenic therapies.

Overcoming resistance to antiangiogenic therapies.

http://www.wikidata.org/entity/Q38024765

about

Pharmacologic resistance in colorectal cancer: a review Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.Fucoidan as a marine anticancer agent in preclinical development MicroRNA-192 suppresses liver metastasis of colon cancer.Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis.Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases.Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Endoglin is necessary for angiogenesis in human ovarian carcinoma-derived primary endothelial cells.Role of targeted agents in metastatic colorectal cancer.MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.Recruitment of CD11b+Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody.Targeted therapy: resistance and re-sensitization.Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer.Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer.Development of an Experimental Model for Analyzing Drug Resistance in Colorectal Cancer.Impaired tumor growth and angiogenesis in mice heterozygous for Vegfr2 (Flk1)

P2860

Q26769850-E84FAAE6-305A-41FA-8F47-EB4F101805E2 Q27853358-43487FFB-4680-467B-8A0D-C6A7C4FAAC94 Q28397061-4AEE2441-A794-4A76-8DB9-74440693E347 Q33594662-F9F6C064-4BE5-4F8C-A89C-70D2AD38B4D5 Q33618582-A4506136-2AAB-4970-AC76-1014367E51EB Q34537725-D7041500-F038-4F5B-BC4B-F3980E4577E4 Q34639841-3C3F5058-221B-4997-AD37-1B4371470E2C Q34747015-E526CF5E-CB82-4CC1-9C35-BDAF52669F02 Q34825323-0B0B0929-2CAF-405E-81FC-4B78FA72C789 Q35637857-FBE91431-6CFE-4F15-A57F-BAC3B6CE5517 Q35780797-A12482D3-3193-4610-BC40-14615E8DEF05 Q35929796-2A1AE79C-E03D-4B25-9B92-6FCE84C369BE Q36286833-A6A72578-508D-45F0-B511-02DAD7BAFE9B Q37589238-FFD678A2-8598-4B59-9A53-59374BE37F9D Q38104294-A1178133-214D-4E04-BBF9-DAC83B1AF8D2 Q38247982-D431260B-A079-46B9-9A29-08C391D06DD5 Q38969661-D1389726-5686-4AF5-A37F-9EF751E842DF Q39044411-3DFB99EA-3177-4898-B667-AD63680B2661 Q40978947-921D269E-9B62-4F60-BB3A-31696D08C8AB Q41356511-A5FC5432-E469-4536-92A7-2B948FEEEB5D Q43062212-B2EC0C10-2C8B-4E5E-9093-2158D6DB4176 Q55280505-D44735AB-B25C-4CEB-B193-D0B9E7847053 Q55456514-0AC3CA7F-4B6B-4D3F-B4BA-76C77C995A75 Q57041735-527ABE69-E813-4B53-ADC6-041F4786FCF2

P2860

Overcoming resistance to antiangiogenic therapies.

http://www.wikidata.org/entity/Q38024765

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Overcoming resistance to antiangiogenic therapies.

@en

type

label

Overcoming resistance to antiangiogenic therapies.

@en

prefLabel

Overcoming resistance to antiangiogenic therapies.

@en

P1433

Q38024765-E70AA4F4-339B-40B4-B954-7E70F19686D9

P1476

Q38024765-FB875D3A-8A3B-4DED-BDDD-ED21CEB75FA9

P2093

Q38024765-584C4B5C-5E25-44A2-AFB6-0A772895CBDD

P2860

Q38024765-057C69A2-F60B-45BE-913B-A80CA902EC24

Q38024765-09A2E51D-33FE-4147-88D6-1A5B6F2F6A94

Q38024765-0ADD832C-E899-4075-A03F-7FC789FD0B4A

Q38024765-0D03F1E3-F189-4F68-8270-0E10DCA7B082

Q38024765-0EEA27C9-F2CC-4573-BE61-EA271921664C

Q38024765-10209677-1C74-4143-B891-CFDA965EAB18

Q38024765-11FA16C9-E401-4299-B331-95310683DF6E

Q38024765-13655491-0EB6-4746-9179-8B2EFD2955BB

Q38024765-16F7AD04-D5ED-4D94-B2E8-459F0B0445B3

Q38024765-1BF2EA60-AD1D-4584-8E76-C0910FBEA4BD

P304

Q38024765-4558D157-6A7D-4F4E-97DF-1C3FCCD3C834

P31

Q38024765-8CA0E67C-7766-43CD-ACC8-B5FD64C8BD14

P356

Q38024765-F34C1012-C34E-4E79-86E7-7688FD1B1A11

P433

Q38024765-7CB45A81-8DB0-4E9F-9A41-2421FBB93AA5

P478

Q38024765-C0545152-71A9-479A-A80E-19382168FC59

P50

Q38024765-31931D24-C526-49FD-8F77-04D17D543A43

Q38024765-D12BAA63-FEB8-464A-9B40-18099FA643B6

P577

Q38024765-25A4986D-3C8F-4425-9027-C9211CF994A6

P5875

Q38024765-50045330-0A5C-44D7-9F2E-ECBC571BA688

P698

Q38024765-32135F90-F3EA-4FCE-BD4B-351E46227748

P932

Q38024765-EE61F7BE-DB52-4E08-AB61-020559C3CE23

P356

THEONCOLOGIST.2012-0068

P1433

P1476

Overcoming resistance to antiangiogenic therapies.

@en

P2093

Hans Prenen

http://www.w3.org/2001/XMLSchema#string

P2860

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor

HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Modes of resistance to anti-angiogenic therapy

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing

P304

1039-1050

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2012-0068

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Massimiliano Mazzone

P577

2012-07-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228446723

http://www.w3.org/2001/XMLSchema#string

P698

22773560

http://www.w3.org/2001/XMLSchema#string

P932

3425522

http://www.w3.org/2001/XMLSchema#string